Noble Capital Markets Initiates Equity Research Coverage on Cosmos Health with Outperform Rating and $1.40 Price Target
Noble's valuation applies 1.42 times its 2027 revenue estimate, below the peer group average of 1.5 times.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) announced Noble Capital Markets initiated company-sponsored research coverage with an Outperform rating and a $1.40 price target. The target is approximately 493% above the October 27, 2026 closing price of $0.236.
Noble forecasts revenue of $90.0 million in 2026, up approximately 38%, followed by $131.2 million in 2027 and $160.8 million in 2028; adjusted EBITDA, an adjusted earnings measure, turning positive at $3.9 million in 2026 and reaching $27.4 million in 2028; and gross margin rising from 12.1% in 2025 to 31.5% in 2028. Its fourth-quarter 2026 estimates are $35.7 million in revenue, $6.4 million in adjusted EBITDA and 40.1% gross margin. Free cash flow is forecast to turn positive at $10.0 million in 2027 and reach $16.8 million in 2028. These are analyst estimates, not reported results.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.Noble forecasts 2026 revenue of $90.0 million, up approximately 38%, then $131.2 million in 2027 and $160.8 million in 2028.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Noble forecasts adjusted EBITDA turning positive at $3.9 million in 2026, then $16.7 million in 2027 and $27.4 million in 2028.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Noble expects gross margin to expand from 12.1% in 2025 to 31.5% in 2028.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Noble forecasts free cash flow turning positive at $10.0 million in 2027, increasing to $16.8 million in 2028.
- Minor point. Forward-looking: it has not happened yet and may not happen.Noble initiated coverage at Outperform; its $1.40 target is approximately 493% above the October 27, 2026 close of $0.236.
2 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.Noble forecasts fourth-quarter 2026 revenue of $35.7 million, adjusted EBITDA of $6.4 million and gross margin of 40.1%.
- Minor point. Forward-looking: it has not happened yet and may not happen.Noble expects higher-margin revenue to grow from approximately 25% of total revenue in 2026 to approximately 44% in 2028.
Negative
- None.
Details
Market Reaction – COSM
On Oct 28, the day this news came out, the latest delayed price for COSM is 0.55% above the previous close. Argus tracked a peak move of +2.4% during the session. Our momentum scanner has recorded 5 alerts for this stock so far that day. The latest delayed price is $0.24. Relative volume is elevated at 2.9x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Price target
- $1.40 per share
- Noble Capital Markets' Outperform coverage
- Valuation multiple
- 1.42x
- Price target based on Noble's 2027 revenue estimate
- Revenue estimate
- $90.0 million
- 2026, Noble forecast
- Revenue estimate
- $131.2 million
- 2027, Noble forecast
- Revenue estimate
- $160.8 million
- 2028, Noble forecast
- Fourth-quarter revenue estimate
- $35.7 million
- Q4 2026, Noble forecast
- Adjusted EBITDA estimate
- $6.4 million
- Q4 2026, Noble forecast
- Adjusted EBITDA estimate
- $27.4 million
- 2028, Noble forecast
Historical Context
-
Management had forecast 2026 revenue above $90 million, implying Q4 revenue of $35.7 million or more.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
enterprise value financial
good manufacturing practices regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, IL / ACCESS Newswire / October 28, 2026 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that Noble Capital Markets ("Noble") has initiated company-sponsored equity research coverage on the Company with an Outperform rating and a price target of
The research report, authored by Noble Capital Markets Senior Research Analyst Michael Kupinski, is available on Channelchek, along with the latest news, market data, and additional information on Cosmos Health (COSM).
Management encourages investors to review the report and visit Channelchek for ongoing coverage and updates.
The report, titled "Building a Higher-Margin Healthcare Platform," includes the following key estimates and conclusions:
- Rating and price target: Outperform rating with a
$1.40 price target, approximately493% above the$0.236 closing price on Tuesday, October 27, 2026 - Valuation: the price target is based on 1.42 times Noble's 2027 revenue estimate of
$131.2 million , implying an enterprise value of approximately$186.3 million , a modest discount to the peer group average of 1.5 times - Revenue growth: Noble forecasts revenue of
$90.0 million in 2026, up approximately38% , rising to$131.2 million in 2027 and$160.8 million in 2028 - Record fourth quarter: Noble forecasts fourth-quarter 2026 revenue of
$35.7 million , adjusted EBITDA of$6.4 million and gross margin of40.1% - Margin expansion: Noble expects consolidated gross margin to expand from
12.1% in 2025 to31.5% in 2028 - Earnings growth: Noble forecasts adjusted EBITDA turning positive at
$3.9 million in 2026 and increasing to$16.7 million in 2027 and$27.4 million in 2028 - Cash flow: Noble forecasts free cash flow turning positive at
$10.0 million in 2027 and increasing to$16.8 million in 2028
Noble identifies the Company's proprietary products, led by its U.S. direct-to-consumer business, and Cana Laboratories' contract manufacturing operations as the principal drivers of its shift toward higher-margin revenue, which Noble expects to grow from approximately
Greg Siokas, CEO of Cosmos Health, stated: "We are delighted to welcome Noble's coverage of Cosmos Health. For years, we have been building a vertically integrated healthcare platform, and today that platform is entering its most exciting phase, with growth coming from our proprietary brands, our expanding manufacturing operations and our rapidly scaling U.S. subscription business.
"Coverage from a firm with Noble's track record helps a much broader investor audience discover the transformation underway at Cosmos Health. We are energized by the opportunity ahead, and we are determined to keep executing and delivering results that create lasting value for our shareholders."
About Noble Capital Markets
Established in 1984, Noble Capital Markets is an SEC / FINRA registered full-service investment bank and advisory firm with an award-winning research team and proprietary investor distribution platform. Noble delivers middle market expertise to entrepreneurs, corporations, financial sponsors, and investors. Over the past 40 years, Noble has raised billions of dollars for companies and published more than 45,000 equity research reports.
About Channelchek
Noble launched www.channelchek.com in 2018 - an investor community dedicated exclusively to public emerging growth companies and their industries. Channelchek is the first service to offer institutional-quality research to the public, for FREE at every level without a subscription. More than 7,000 public emerging growth companies are listed on the site, and content including equity research, webcasts, and industry articles.
About Cosmos Health Inc.
Cosmos Health Inc. (NASDAQ:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans," and similar expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could," generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company's control, including, but not limited to: the Company's ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company's business, operations, and the economy in general; the Company's ability to successfully develop and commercialize its proprietary products and technologies; the timing, execution, regulatory clearance, valuation, structuring, and completion of any potential asset-backed or tokenized financing program; the legal, regulatory, and technological risks associated with digital assets and blockchain-based financial structures; the conversion of contract manufacturing pipeline volumes into production and revenue, including the timing, volume and terms of orders placed under multi-year agreements; the realization of anticipated gross margins; the timing, cost and completion of planned capital investments; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties - many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us - as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC's website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
Noble Capital Markets was compensated by the Company for a research report production and distribution, including utilizing it in a press release. The research report does not take into account the investment objectives, financial situation, or particular needs of any particular person. The research report does not provide all information material to an investor's decision about whether or not to make any investment. Any discussion of risks in the research report is not a disclosure of all risks or a complete discussion of the risks mentioned. Noble Capital Markets is registered as a securities broker-dealer with the U.S. Securities and Exchange Commission and is a member of FINRA. The report does not constitute investment advice or an offer to buy or sell securities. The analysts' opinions are separate from and are not influenced by Noble Capital Markets' investment banking or trading departments.
ALL INFORMATION IN THE RESEARCH REPORT IS PROVIDED "AS IS" WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND.
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What rating and price target did Noble assign to Cosmos Health?
Noble initiated company-sponsored coverage of Cosmos Health with an Outperform rating and a $1.40 per-share price target. That target is approximately 493% above the $0.236 closing price on October 27, 2026. The rating and target are Noble's views.
How did Noble value Cosmos Health for its price target?
Noble based its target on 1.42 times its 2027 revenue estimate of $131.2 million, implying an enterprise value of approximately $186.3 million. The valuation multiple is below the peer group average of 1.5 times.
What does Noble identify as the drivers of Cosmos Health's higher-margin revenue?
Noble identifies proprietary products, led by the U.S. direct-to-consumer business, and Cana Laboratories' contract manufacturing operations as the principal drivers. It expects higher-margin revenue to increase from approximately 25% of total revenue in 2026 to approximately 44% in 2028.